Newsroom
AI-based heart failure phenotyping enables high-validity evidence
Researchers from Amgen, Harvard, Providence, and Verantos published a paper in BMJ Open comparing the use of various types of data and technology in understanding heart failure subgroups and associated signs, symptoms, and comorbidities. Accuracy was 45% greater using Verantos AI than traditional approaches. This groundbreaking work highlights Verantos’ market-leading technology and how better treatment decisions can be made using granular heart failure subgroups extracted from routinely collected data.
Read at the original outletAll news